Recent performance snapshot

Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh investor attention after a mixed run, with the stock down 2.9% over the past day and 4.0% over the past week, but up over the past month and past 3 months.

Zooming out, Teva’s recent pullback comes after a strong run, with an 8.5% 1 month share price return and a 1 year total shareholder return of 102%, suggesting momentum has been building rather than fading.

If Teva’s move has you thinking about what else could be setting up for strong healthcare trends, now is a good time to screen for 32 healthcare AI stocks

With Teva shares up sharply over the past year and trading at a discount to some analysts’ price targets and certain intrinsic value models, you need to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 14.5% Undervalued

Based on the most followed narrative, Teva’s fair value of $40.09 sits above the last close at $34.29, framing the stock as undervalued on that framework.

Teva's strategic focus and rapid execution on expanding its branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.

Want to see what sits behind that higher margin story? The narrative leans on modest revenue growth, rising profitability, and a richer earnings multiple to bridge today’s price to that fair value.

Result: Fair Value of $40.09 (UNDERVALUED)

However, that upside story can fray if execution on the R&D and biosimilars pipeline disappoints, or if Teva’s more than US$15b debt load constrains flexibility.

Another Angle On Valuation

So far, the story leans on future earnings and fair value around $40.09. Today Teva trades on a P/E of 25.5x versus 18.8x for peers and a 14.8x US Pharmaceuticals average, and above a fair ratio of 21.5x, which points to valuation risk rather than a clear bargain. The key question is whether the premium is justified or whether optimism is running ahead of itself.

Next Steps

With mixed signals around value, risk, and reward, the key question is what matters most to you right now. Move quickly, review the details, and weigh the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Teva has caught your eye, do not stop there. Broadening your watchlist across different types of opportunities can help you spot setups you might otherwise miss.

• Spot potential value opportunities early by scanning screener containing 22 high quality undiscovered gems that combine solid fundamentals with limited market attention.
• Strengthen your downside protection by focusing on companies in the 66 resilient stocks with low risk scores that score well on resilience and risk checks.
• Build a foundation of financially robust holdings by filtering for the solid balance sheet and fundamentals stocks screener (45 results) and stress test how each stock might hold up when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.